🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07742709
Active, not recruiting Observational

Study on the Rapid Diagnostic Value of Sudden Clap Provocation Test in Psychogenic Nonepileptic Seizures

NCT07742709 · tracked via the Priya Life Science China tracker
Sponsor
Xijing Hospital
Phase
Observational
Started
2026-02-01
Last updated
2026-08-03

Condition(s) studied

EpilepsyPsychogenic Non-epileptic Seizures

Investigational drug(s) / intervention(s)

Abrupt Clap Provocation Test

Abrupt Clap Provocation Test: This intervention is the abrupt clap provocation diagnostic test, a behavioral stimulation diagnostic method unique to this trial. The operator delivers sudden, loud hand-clap stimuli at a fixed distance in a quiet environment, records the subjects' auditory sensitivity, physical reactions and behavioral manifestations in real time, and evaluates the response threshold to acoustic stimulation. No drugs, medical devices or other physical stimulation operations are involved in this intervention; it only relies on manual clapping to complete the provocation detection, which is different from drug intervention, imaging examination and other test means in this study.

Study summary

To explore the clinical value of the sudden clap provocation test in the differential diagnosis between epileptic seizures and psychogenic non-epileptic seizures, so as to provide a new strategy for rapid, low-cost differential diagnosis. This study is a prospective, single-center, diagnostic trial. This study is a single-center, prospective study that plans to recruit 400 patients who have "convulsive seizure" events during video electroencephalogram monitoring. A standardized sudden clap test is adopted, and one sudden clap test is performed during each clinically detected seizure episode, with the study period covering the entire VEEG monitoring process (approximately 24 hours). During the trial, the patient's basic treatment plan and VEEG monitoring process remain unchanged, and data analysis and diagnostic efficacy evaluation will be carried out after the VEEG monitoring is completed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Continuous video-electroencephalogram (VEEG) monitoring duration of 24 hours or longer * At least one recorded episode during VEEG monitoring with prominent abnormal limb movements (such as convulsive episodes) * Successful administration of the standardized Abrupt Clap Provocation Test (ACPT) during the clinical ictal phase * Episodes definitively diagnosed as epileptic seizures (ES) or confirmed as psychogenic non-epileptic seizures (PNES) at the highest certainty level (Level 4: documented/confirmed) according to the International League Against Epilepsy (ILAE) criteria * Complete clinical and demographic data available Exclusion Criteria: * Coexisting severe hearing impairment or documented ear disease, rendering the patient unable to effectively perceive normal auditory stimuli * Episodes definitively diagnosed as other non-epileptic paroxysmal disorders (such as syncope, paroxysmal kinesigenic dyskinesia, or sleep disorders) * Episodes occurring out of the camera view, obscured, or recorded with poor video quality, preventing accurate assessment of ictal behavioral responses to the clap stimulus * Severe lack of clinical data, loss to follow-up, or refusal/withdrawal of informed consent

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
The First Affiliated Hospital of Air Force Medical University (Xijing Hospital) Xian Shanxi
No.127 Changle West Road, Xincheng District, Xi'an, Shaanxi 710048, China Shanxi China
The First Affiliated Hospital of Air Force Medical University (Xijing Hospital) Shanxi China

More Xijing Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07742709 on ClinicalTrials.gov ↗ ← All trials in China